We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Werfen and Thermo Fisher Enter Into Worldwide Distributor Agreement for Hemostasis Testing Workcell

By LabMedica International staff writers
Posted on 05 May 2023

Werfen (Barcelona, Spain) has entered into a new long-term, exclusive partnership agreement with Thermo Fisher Scientific (Waltham, MA, USA) to globally distribute the TCAutomation laboratory automation system, specifically tailored for hemostasis diagnostics. More...

This agreement, a follow-up to their exclusive contract signed in 2015, allows Werfen to continue offering HemoCell Specialized Lab Automation, which has the largest global installed base of hemostasis automation workcells.

HemoCell streamlines laboratory workflow by integrating all stages of testing. It comprises Werfen's ACL TOP Family 50 Series Hemostasis Testing Systems and HemoHub Intelligent Data Manager, paired with Thermo Fisher's TCAutomation system. This combination standardizes sample processing, ensuring consistent turnaround times for routine and urgent samples. This efficiency frees up laboratory staff, improving overall lab efficiency and quality of work. Ultimately, HemoCell contributes to improving the quality of care while minimizing costs.

The TCAutomation laboratory automation system is designed to provide truly efficient workflow for laboratories through its modularity, flexibility, and connectivity. It aids in managing escalating workloads and improving quality. By offering flexible and cost-effective solutions, it automates the most labor-intensive pre- and post-analytical tasks. Its open concept enables direct interfaces with a broad range of analyzers. The TCAutomation system can be easily expanded with additional modules, thereby helping laboratories adapt to future needs and requirements and boost efficiency, productivity, and safety.

"This significant continuation of our long-term distribution agreement is a testament to the strength of our partnership with Thermo Fisher Scientific," said Remo Tazzi, Vice President, Worldwide Marketing and Service, Hemostasis and Acute Care Diagnostics at Werfen. "It also speaks volumes about the success of HemoCell, and the quality of Werfen's workflow experts, their innovative tools and processes, and the value they offer hospital laboratories around the world."

Related Links:
Werfen 
Thermo Fisher Scientific 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.